PRETREATMENT CYTOGENETIC ABNORMALITIES ARE PREDECTIVE OF INDUCTION SUCCESS IN ADULT PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA

Acute myelogenous leukemia is a heterogenous group of genetically defined diseases.It is the most common type of acute leukemia among adults, comprising approximately 80 to 85% of cases of acute leukemia diagnosed in individuals greater than 20 years of age, currently; more than 80% of young adults can achieve CR.For optimal treatment approaches both a precise diagnosis and prognostic parameters that determine response to therapy and survival are needed.So far, the karyotype of the AML blasts is the most important independent prognostic factor.Not only the response to standard induction and consolidation chemotherapy is heavily influenced by the specific karyotypic abnormalities identified, but also the post remission therapy can reasonably be tailored to individual patients based on the prognosis predicted by their diagnostic karyotype.This study aimed to assess the influence of pre-treatment cytogenetic abnormalities as a predictive of induction success in adult patients with de novo acute myeloid leukemia.Thirty adult patients with de novo acute myeloid leukemia were included in our study with median age of 34.5years (range from 17-55), twenty one patients (70%) out of the thirty were male while nine patients (30%) were females with male to female ratio 2.3:1., all patients were subjected to Complete medical history, and thorough Physical examination, Routine laboratory investigations, Cytogenetic analysis using G banding technique.